GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » ROA %
中文

CSL (CSLLY) ROA % : 10.34% (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is CSL ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. CSL's annualized Net Income for the quarter that ended in Dec. 2023 was $3,802 Mil. CSL's average Total Assets over the quarter that ended in Dec. 2023 was $36,769 Mil. Therefore, CSL's annualized ROA % for the quarter that ended in Dec. 2023 was 10.34%.

The historical rank and industry rank for CSL's ROA % or its related term are showing as below:

CSLLY' s ROA % Range Over the Past 10 Years
Min: 6.82   Med: 16.54   Max: 23.83
Current: 6.82

During the past 13 years, CSL's highest ROA % was 23.83%. The lowest was 6.82%. And the median was 16.54%.

CSLLY's ROA % is ranked better than
92.09% of 1555 companies
in the Biotechnology industry
Industry Median: -35.41 vs CSLLY: 6.82

CSL ROA % Historical Data

The historical data trend for CSL's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL ROA % Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.62 15.14 14.13 9.70 6.79

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.93 3.82 10.18 3.19 10.34

Competitive Comparison of CSL's ROA %

For the Biotechnology subindustry, CSL's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's ROA % distribution charts can be found below:

* The bar in red indicates where CSL's ROA % falls into.



CSL ROA % Calculation

CSL's annualized ROA % for the fiscal year that ended in Jun. 2023 is calculated as:

ROA %=Net Income (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=2194/( (28346+36234)/ 2 )
=2194/32290
=6.79 %

CSL's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=3802/( (36234+37304)/ 2 )
=3802/36769
=10.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


CSL  (OTCPK:CSLLY) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=3802/36769
=(Net Income / Revenue)*(Revenue / Total Assets)
=(3802 / 15608)*(15608 / 36769)
=Net Margin %*Asset Turnover
=24.36 %*0.4245
=10.34 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


CSL ROA % Related Terms

Thank you for viewing the detailed overview of CSL's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


CSL (CSLLY) Business Description

Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

CSL (CSLLY) Headlines

From GuruFocus

CSL and uniQure Win 2023 Prix Galien USA Award

By PRNewswire 10-27-2023